Molecular Testing for Stage IV Non–Small Cell Lung Cancer Patients With Targetable Mutations Following Disease Progression

Archives of Pathology and Laboratory Medicine - United States
doi 10.5858/arpa.2018-0111-ed
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Archives of Pathology and Laboratory Medicine

Related search

P1.13-03 Ensartinib Treatment Beyond Disease Progression in Stage IV ALK+ Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-05 Mature Progression-Free Survival in Stage IV Non-Small Cell Lung Cancer Patients Treated With Pemetrexed Maintenance Therapy

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

EGFR Mutations Status for Non-Small-Cell Lung Cancer Patients

Sveikatos mokslai
2016English

HER2 Mutations in Chinese Patients With Non-Small Cell Lung Cancer

Oncotarget
Oncology
2016English

Image Features for the Future in Stage IV Non-Small Cell Lung Cancer

English

P2.03-08 Molecular Spectrum of Patients With MSH2 Mutations in Chinese Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.01-12 Ramucirumab+Docetaxel Usage Following Rapid Disease Progression in Real World Advanced Non-Small Cell Lung Cancer Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Pembrolizumab-Induced Obstructive Bronchiolitis in a Patient With Stage IV Non-Small-Cell Lung Cancer

Current Oncology
Oncology
2019English

P1.03-01 Association of APC Mutations With Chinese Patients Molecular Spectrum in Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy